Publications by authors named "Mathias Locher"

Claim this Profile
D
Discovery and characterization of COVA322, a clinical-stage bispecific TNF/IL-17A inhibitor for the treatment of inflammatory diseases.
Michela Silacci, Wibke Lembke, Richard Woods, Isabella Attinger-Toller, Nadja Baenziger-Tobler, Mathias Locher

MAbs· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nonclinical safety testing of biopharmaceuticals--Addressing current challenges of these novel and emerging therapies.
Frank R Brennan, Andreas Baumann, Guenter Blaich, Lolke de Haan, Rajni Fagg, Mathias Locher

Regul Toxicol Pharmacol· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New challenges and opportunities in nonclinical safety testing of biologics.
Andreas Baumann, Kelly Flagella, Roy Forster, Lolke de Haan, Sven Kronenberg, Mathias Locher

Regul Toxicol Pharmacol· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells.
Sandrine d'Argouges, Sandra Wissing, Christian Brandl, Nadja Prang, Ralf Lutterbuese, Mathias Locher

Leuk Res· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class.
Klaus Brischwein, Larissa Parr, Stefan Pflanz, Jörg Volkland, John Lumsden, Mathias Locher

J Immunother· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exchanging human Fcgamma1 with murine Fcgamma2a highly potentiates anti-tumor activity of anti-EpCAM antibody adecatumumab in a syngeneic mouse lung metastasis model.
Petra Lutterbuese, Klaus Brischwein, Robert Hofmeister, Sandrine Crommer, Grit Lorenczewski, Mathias Locher

Cancer Immunol Immunother· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A human monoclonal IgG1 potently neutralizing the pro-inflammatory cytokine GM-CSF.
Eva-Maria Krinner, Tobias Raum, Silke Petsch, Sandra Bruckmaier, Ioana Schuster, Mathias Locher

Mol Immunol· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I study with adecatumumab, a human antibody directed against epithelial cell adhesion molecule, in hormone refractory prostate cancer patients.
Ralf Oberneder, Dorothea Weckermann, Beatrice Ebner, Cornelia Quadt, Petra Kirchinger, Mathias Locher

Eur J Cancer· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potent inhibition of local and disseminated tumor growth in immunocompetent mouse models by a bispecific antibody construct specific for Murine CD3.
Bernd Schlereth, Petra Kleindienst, Iduna Fichtner, Grit Lorenczewski, Klaus Brischwein, Mathias Locher

Cancer Immunol Immunother· July 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
N-Glucuronidation of the antiepileptic drug retigabine: results from studies with human volunteers, heterologously expressed human UGTs, human liver, kidney, and liver microsomal membranes of Crigler-Najjar type II.
Jürgen Borlak, Antje Gasparic, Mathias Locher, Hubert Schupke, Robert Hermann

Metabolism· June 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High concentrations of therapeutic IgG1 antibodies are needed to compensate for inhibition of antibody-dependent cellular cytotoxicity by excess endogenous immunoglobulin G.
Susanne Preithner, Stefanie Elm, Sandra Lippold, Mathias Locher, Andreas Wolf

Mol Immunol· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors.
Klaus Brischwein, Bernd Schlereth, Benjamin Guller, Carola Steiger, Andreas Wolf, Mathias Locher

Mol Immunol· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intranasal loteprednol etabonate in healthy male subjects: pharmacokinetics and effects on endogenous cortisol.
Robert Hermann, Mathias Locher, Marianne Siebert-Weigel, Nicole LaVallee, Hartmut Derendorf

J Clin Pharmacol· May 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of R(+)alpha-lipoic acid on pyruvate metabolism and fatty acid oxidation in rat hepatocytes.
Jennie L Walgren, Zainab Amani, JoEllyn M McMillan, Mathias Locher, Maria G Buse

Metabolism· February 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic interaction between retigabine and lamotrigine in healthy subjects.
Robert Hermann, Norbert G Knebel, Georg Niebch, Lyette Richards, Juergen Borlak, Mathias Locher

Eur J Clin Pharmacol· April 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic/pharmacodynamic modeling of luteinizing hormone (LH) suppression and LH surge delay by cetrorelix after single and multiple doses in healthy premenopausal women.
Nelamangala V Nagaraja, Birgit Pechstein, Katharina Erb, Christine Klipping, Robert Hermann, Mathias Locher

J Clin Pharmacol· March 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis